Welcome to Multibagg AI
Log in to access personalized features
IRIS
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Research powered by GOALZEN CAPITAL SERVICES PRIVATE LIMITED · SEBI Research Analyst INH000013448
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discovery themes featuring this stock
Orchid Pharma Limited is a vertically integrated pharmaceutical company manufacturing APIs and finished dosage forms, with USFDA‑ and MHRA‑compliant facilities, established R&D centres and a recently consolidated platform following the Dhanuka Laboratories merger; the company focuses on cephalosporins, sterile injectables and complex anti‑infective molecules across regulated and non‑regulated markets.
On a combined Orchid‑Dhanuka basis, Fiscal 2026 revenue was INR1,233 crores (restated), while Q1 FY27 revenue improved to INR304 crores, a ~15% year‑on‑year increase; gross margin expanded ~300 basis points to 33% and EBITDA rose to INR25 crores from INR10 crores, indicating early signs of margin recovery despite industry overcapacity and pricing pressure.
Orchid Pharma Limited is executing two material projects: a large INR750 crore 7‑ACA backward‑integration fermentation plant targeting first commercial batches by March 2027, and a cefiderocol sterile facility with commissioning by December 2026; these projects are strategically intended to reduce import dependency, improve margin capture, and enable sterile injectable and regulated market expansion.
The company is commercializing novel assets and partnerships: Exblifep shows strong early traction with a Russia licensing deal (~USD178 million ten‑year value) and rapid volume growth in Europe, while the Allecra asset acquisition for Cefepime‑Enmetazobactam and GARDP engagement for cefiderocol aim to open humanitarian and emerging market channels, diversifying Orchid Pharma Limited’s revenue sources.
Near‑term risks remain material: persistent overcapacity, aggressive pricing in non‑regulated markets, and typical fermentation scale‑up uncertainties; Orchid Pharma Limited emphasizes disciplined cost control, phased integration synergies from the merger, and cautious commercialization to progressively strengthen profitability rather than expecting immediate straight‑line recovery.
Pharmaceuticals & Biotechnology
Pharmaceuticals
5,341 Cr
Moderate Risk
540.1
37.0
0.6
3.4
1,142.65
471.30
Sales CAGR
Profit CAGR
ROE
ROCE
Bearish
3
Neutral
6
Bullish
5
Bearish
34
Neutral
6
Bullish
6
Bearish
31
Neutral
0
Bullish
1
View Standalone
View Standalone
Bearish
31
Neutral
0
Bullish
1
Bearish
31
Neutral
0
Bullish
1
Bearish
31
Neutral
0
Bullish
1
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
1035.80 | 6,013 Cr | 39.04 | 5.51 | 0.19 | 12.92 | 14.30 | 8.38 | ||
176.90 | 5,947 Cr | 3.75 | 4.44 | 0.00 | 116.01 | 80.89 | 72.98 | ||
1133.60 | 5,612 Cr | 40.87 | 5.60 | 0.00 | 13.31 | 14.70 | 8.17 | ||
180.00 | 5,426 Cr | 32.28 | 3.02 | 0.54 | 7.65 | 10.29 | 6.50 | ||
830.00 | 5,341 Cr | 540.09 | 3.41 | 0.00 | 1.34 | 1.62 | 0.62 | ||
2550.75 | 4,955 Cr | 44.63 | 8.18 | 0.80 | 15.89 | 20.87 | 9.93 | ||
360.00 | 4,879 Cr | 100.22 | 6.44 | 0.15 | — | — | 0.00 | ||
| Median: 7 Co. | — | 830.00 | 5,426 Cr | 40.87 | 5.51 | 0.15 | 13.11 | 14.50 | 8.17 |
Orchid Pharma Ltd (ORCHPHARMA) is currently trading at 830.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Orchid Pharma Limited is a vertically integrated pharmaceutical company manufacturing APIs and finished dosage forms, with USFDA‑ and MHRA‑compliant facilities, established R&D centres and a recently consolidated platform following the Dhanuka Laboratories merger; the company focuses on cephalosporins, sterile injectables and complex anti‑infective molecules across regulated and non‑regulated markets. On a combined Orchid‑Dhanuka basis, Fiscal 2026 revenue was INR1,233 crores (restated), while Q1 FY27 revenue improved to INR304 crores, a ~15% year‑on‑year increase; gross margin expanded ~300 basis points to 33% and EBITDA rose to INR25 crores from INR10 crores, indicating early signs of margin recovery despite industry overcapacity and pricing pressure. Orchid Pharma Limited is executing two material projects: a large INR750 crore 7‑ACA backward‑integration fermentation plant targeting first commercial batches by March 2027, and a cefiderocol sterile facility with commissioning by December 2026; these projects are strategically intended to reduce import dependency, improve margin capture, and enable sterile injectable and regulated market expansion. The company is commercializing novel assets and partnerships: Exblifep shows strong early traction with a Russia licensing deal (~USD178 million ten‑year value) and rapid volume growth in Europe, while the Allecra asset acquisition for Cefepime‑Enmetazobactam and GARDP engagement for cefiderocol aim to open humanitarian and emerging market channels, diversifying Orchid Pharma Limited’s revenue sources. Near‑term risks remain material: persistent overcapacity, aggressive pricing in non‑regulated markets, and typical fermentation scale‑up uncertainties; Orchid Pharma Limited emphasizes disciplined cost control, phased integration synergies from the merger, and cautious commercialization to progressively strengthen profitability rather than expecting immediate straight‑line recovery.
Over the past 52 weeks, Orchid Pharma Ltd has traded between a low of ₹471.30 and a high of ₹1,142.65. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Orchid Pharma Ltd has a market capitalization of approximately 5,341.46. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Orchid Pharma Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 540.09 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 5,341.46 Cr, Orchid Pharma Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Orchid Pharma Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Orchid Pharma Ltd is 540.09. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Orchid Pharma signed a licensing and supply agreement giving Pharmasyntez exclusive rights to register and commercialise Exblifep in Russia, subject to regulatory approval.
The scheme became effective on July 10, 2026, after completion of prescribed conditions and related filings.
Yes. The NCLT Chennai Bench sanctioned the scheme, with the order pronounced on June 05, 2026 and uploaded on the NCLT website on June 11, 2026.
Orchid Pharma signed an exclusive licensing and supply agreement under which Pharmasyntez will register and commercialise Exblifep in Russia, while Orchid supplies the finished dosage form.
